🚀 VC round data is live in beta, check it out!
Neumora Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Neumora Therapeutics and similar public comparables like Benitec Biopharma, Akebia Therapeutics, Recbio, Climb Bio and more.
Neumora Therapeutics Overview
About Neumora Therapeutics
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Founded
2019
HQ
Employees
110
Website
Sectors
Financials (LTM)
EV
$251M
Neumora Therapeutics Financials
Neumora Therapeutics reported last 12-month revenue of — and negative EBITDA of ($215M).
In the same LTM period, Neumora Therapeutics generated — in gross profit, ($215M) in EBITDA losses, and had net loss of ($222M).
Revenue (LTM)
Neumora Therapeutics P&L
In the most recent fiscal year, Neumora Therapeutics reported revenue of — and EBITDA of ($233M).
Neumora Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($215M) | XXX | ($233M) | XXX | XXX | XXX |
| Net Profit | ($222M) | XXX | ($237M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Neumora Therapeutics Stock Performance
Neumora Therapeutics has current market cap of $379M, and enterprise value of $251M.
Market Cap Evolution
Neumora Therapeutics' stock price is $2.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $251M | $379M | -4.4% | XXX | XXX | XXX | $-1.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeumora Therapeutics Valuation Multiples
Neumora Therapeutics trades at (1.2x) EV/EBITDA.
EV / Revenue (LTM)
Neumora Therapeutics Financial Valuation Multiples
As of April 11, 2026, Neumora Therapeutics has market cap of $379M and EV of $251M.
Equity research analysts estimate Neumora Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neumora Therapeutics has a P/E ratio of (1.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $379M | XXX | $379M | XXX | XXX | XXX |
| EV (current) | $251M | XXX | $251M | XXX | XXX | XXX |
| EV/EBITDA | (1.2x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/EBIT | (1.1x) | XXX | (1.0x) | XXX | XXX | XXX |
| P/E | (1.7x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | (1.3x) | XXX | (1.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Neumora Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Neumora Therapeutics Margins & Growth Rates
Neumora Therapeutics' revenue in the last fiscal year grew by —.
Neumora Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.2M for the same period.
Neumora Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (34%) | XXX | (38%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Neumora Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Benitec Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Akebia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| Climb Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Cuorips | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neumora Therapeutics M&A Activity
Neumora Therapeutics acquired XXX companies to date.
Last acquisition by Neumora Therapeutics was on XXXXXXXX, XXXXX. Neumora Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Neumora Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeumora Therapeutics Investment Activity
Neumora Therapeutics invested in XXX companies to date.
Neumora Therapeutics made its latest investment on XXXXXXXX, XXXXX. Neumora Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Neumora Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Neumora Therapeutics
| When was Neumora Therapeutics founded? | Neumora Therapeutics was founded in 2019. |
| Where is Neumora Therapeutics headquartered? | Neumora Therapeutics is headquartered in United States. |
| How many employees does Neumora Therapeutics have? | As of today, Neumora Therapeutics has over 110 employees. |
| Who is the CEO of Neumora Therapeutics? | Neumora Therapeutics' CEO is Paul L. Berns. |
| Is Neumora Therapeutics publicly listed? | Yes, Neumora Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Neumora Therapeutics? | Neumora Therapeutics trades under NMRA ticker. |
| When did Neumora Therapeutics go public? | Neumora Therapeutics went public in 2023. |
| Who are competitors of Neumora Therapeutics? | Neumora Therapeutics main competitors are Benitec Biopharma, Akebia Therapeutics, Recbio, Climb Bio. |
| What is the current market cap of Neumora Therapeutics? | Neumora Therapeutics' current market cap is $379M. |
| Is Neumora Therapeutics profitable? | No, Neumora Therapeutics is not profitable. |
| What is the current EBITDA of Neumora Therapeutics? | Neumora Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Neumora Therapeutics? | Current EBITDA multiple of Neumora Therapeutics is (1.2x). |
| What is the current FCF of Neumora Therapeutics? | Neumora Therapeutics' last 12 months FCF is ($188M). |
| What is the current EV/FCF multiple of Neumora Therapeutics? | Current FCF multiple of Neumora Therapeutics is (1.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.